We think Roche's drug portfolio and industry-leading diagnostics conspire to create maintainable competitive advantages. As the market leader in both biotech and diagnostics, this Swiss healthcare ...

Perjeta has become one of Roche’s fastest-growing and top-selling drugs, thanks in no small part to data from the APHINITY trial which showed that adding it to Herceptin can improve disease-free ...

I tell people I feel blessed to not be diagnosed with cancer in the US. Right now pauses on federal funding, including grants ...

Breast cancer drug Phesgo’s (a fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) sales surged 62% year over year to CHF 1.7 billion. Evrysdi generated sales of CHF 1.6 ...

It finally happened; my hair started falling like autumn leaves, strands dropping wherever I went, leaving a trail of black and grey. As poetic as I make it ...

RHHBY records impressive sales growth in 2024 on the back of strong demand for Vabysmo, Hemlibra, Phesgo and Ocrevus.

Hence, the rising incidence of breast cancer is a crucial driver of the growth of the herceptin biosimilars market. Who Are The Major Industry Players In The Perjeta Market ? Some of the prominent ...

Patients whose metastatic colorectal cancer has progressed following chemotherapy and who lack mutations in the RAS and BRAF ...

Roche Holding AG delivered a strong set of 2024 earnings. Guidance for 2025 suggests this will be a transitional year ahead, ...